Top

Global Metabolic Disorders Therapeutics Market 2016-2020

Category : Medical Devices  | Published Date : Sept-2016 | Pages : 163
enquire GET DISCOUNT
About Metabolic Disorders

Metabolic disorders occur as a result of disruption of chemical processes and conversions occurring in the cells and fluids of the body. This is mainly because of defects in the enzyme; all process in the body are controlled by enzymes. Any disruption in the pathways involved in the development and metabolism of carbohydrates, proteins, fats, and nucleic acids, results in the development of metabolic disorders.

Technavio’s analysts forecast the global metabolic disorders therapeutics market to grow at a CAGR of 4.62% during the period 2016-2020.

Covered in this report 
The report covers the present scenario and the growth prospects of the global metabolic disorders therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of various metabolic disorders including diabetes, obesity, lysosomal storage diseases, and hypercholesterolemia.

The market is divided into the following segments based on geography: 
• Americas
• APAC
• EMEA

Technavio's report, Global Metabolic Disorders Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

Key vendors 
• Novo Nordisk
• Sanofi
• Merck
• AstraZeneca
• Eli Lilly

Other prominent vendors 
• AbbVie
• Actelion Pharmaceuticals
• Adocia
• Aegerion Pharmaceuticals
• Akros Pharma
• Alnylam Pharmaceuticals
• Amarin
• nAmgen
• Amicus Therapeutics
• Arbutus Biopharma
• Arena Pharmaceuticals
• Astellas Pharma
• Atheronova
• Aurobindo Pharma
• Baxalta
• Belrose Pharma
• BHV Pharma
• Biocon
• Biodel
• BioMarin
• Bionaturis
• Biosidus
• Biospherics
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Catabasis Pharmaceuticals
• Cerenis Therapeutics
• Chipscreen Biosciences
• Cipla
• CJ HealthCare
• CKD Bio
• Concord Biotech
• ConjuChem
• CureDm
• CymaBay Therapeutics
• Daewoong
• Daiichi Sankyo
• Dance Biopharm
• DiaMedica
• Diamyd Therapeutics
• Diasome Pharmaceuticals
• DiaVacs
• Dong-A ST
• Eisai
• Elcelyx Therapeutics
• Esperion Therapeutics
• Exsulin
• F. Hoffmann-La Roche
• Gan & Lee Pharmaceuticals
• Generex Biotechnology
• Genfit
• GlaxoSmithKline
• HanAll BioPharma
• Hanmi Pharmaceutical Company
• Hua Medicine
• Iltoo Pharma
• Intarcia Therapeutics
• InteKrin Therapeutics
• Intrexon
• Ionis Pharmaceuticals
• Islet Sciences
• ISU Abxis
• Janssen Pharmaceuticals
• Japan Tobacco
• JCR Pharmaceuticals
• JW Pharmaceuticals
• Kadmon Pharmaceuticals
• Kamada
• KinDex Pharmaceuticals
• Kissei
• Kotobuki
• Kowa Company
• Laboratoires SMB
• Lexicon Pharmaceuticals
• Ligand Pharmaceuticals
• Living Cell Technologies
• Livzon
• LIXTE Biotechnology
• Lupin
• MacroGenics
• Madrigal Pharmaceuticals
• MannKind
• MedImmune
• Melior Pharmaceuticals
• Merrion Pharmaceuticals
• Merz Pharmaceuticals
• Metabolic Solutions Development Company
• Mitsubishi Tanabe Pharma
• Mylan
• Neothetics
• Neuraltus Pharmaceuticals
• NGM Biopharmaceuticals
• NGM Biopharmaceuticals
• Norgine BV
• Novartis
• NuSirt Biopharma
• Oramed
• Orexigen Therapeutics
• Osiris Therapeutics
• Peptron
• Perle Biosciences
• Pfizer
• PhaseBio Pharmaceuticals
• Poxel
• Protalix Biotherapeutics
• Raptor
• Recordati
• Regeneron Pharmaceuticals
• Regeneron Pharmaceuticals
• REGiMMUNE
• Rhythm Pharmaceuticals
• Saniona
• Santaris Pharma
• Santaris Pharma
• Serometrix
• Shionogi
• Shire
• Sigma-Tau
• Sirona Biochem
• Strongbridge Biopharma
• SUN Pharma
• Takeda
• Teva
• Thera technologies 
• Theracos
• Toleranzia
• Tolerion
• Torrent Pharmaceuticals
• Transition Therapeutics
• UCB
• Utrecht Holdings
• VeroScience
• Vivus
• vTv Therapeutics
• XBiotech
• Xeris Pharmaceuticals
• XOMA
• Zafgen
• Zydus Cadila

Market driver 
• Increase in academia-industry collaborations for drug development
• For a full, detailed list, view our report 

Market challenge 
• Low compliance and adherence rates
• For a full, detailed list, view our report 

Market trend 
• Increase in academia-industry collaborations for drug development
• For a full, detailed list, view our report 

Key questions answered in this report 
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors? 

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Pipeline portfolio
• Pipeline portfolio: Global diabetes drugs market
• Pipeline portfolio: Global hyperphosphatemia drugs market
• Pipeline portfolio: Global anti-obesity drugs market
PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 07: Market segmentation by type of disease
• Diabetes
• Obesity
• Hypercholesterolemia
• Lysosomal storage diseases
PART 08: Global diabetes drugs market
• Market overview
• Global type 1 diabetes market
• Global type 2 diabetes drugs market
• Vendors in global diabetes drugs market
PART 09: Global hypercholesterolemia drugs market
• Market overview
• Vendors in global hypercholesterolemia drugs market
PART 10: Global lysosomal storage diseases market
• Market overview
• Vendors in global lysosomal storage disorders drugs market
PART 11: Global anti-obesity drugs market
• Market overview
• Vendors in global anti-obesity drugs market
PART 12: Geographical segmentation
• Global metabolic disorders therapeutics market by geography 2015-2020
• Metabolic disorders therapeutics market in Americas
• Metabolic disorders therapeutics market in EMEA
• Metabolic disorders therapeutics market in APAC
PART 13: Market drivers
• Patient assistance programs
• Special regulatory designations for rare diseases
• Increase in academia-industry collaborations for drug development
PART 14: Impact of drivers
PART 15: Market challenges
• Low compliance and adherence rates
• High cost of therapies
• Complex storage conditions and distribution policies for insulin
PART 16: Impact of drivers and challenges
PART 17: Market trends
• Focus on oral insulin therapies
• Strong and diversified pipeline portfolio
• Strategic collaborations and acquisitions
PART 18: Vendor landscape
• Competitive scenario
• Other prominent vendors
• PART 19: Key vendor analysis
• Novo Nordisk
• Sanof
• Merck
• AstraZeneca
• Eli Lilly
PART 20: Appendix
• List of abbreviations
PART 21: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria and customer segments for metabolic disorder drugsKey buying criteria for metabolic disorders drugs 2015
Exhibit 03: Impact of key customer segments on market 2015
Exhibit 04: Global metabolic disorders therapeutic market snapshot: Developed and emerging markets 2015
Exhibit 05: Global metabolic disorders therapeutics market 2015-2020 ($ billions)
Exhibit 06: Opportunity analysis: Global metabolic disorders therapeutics market
Exhibit 07: Global metabolic disorders therapeutics market: Growth cycle analysis
Exhibit 08: Five forces analysis
Exhibit 09: Global metabolic disorders therapeutics market by type of disease
Exhibit 10: Global metabolic disorders therapeutics market by type (2015-2020)
Exhibit 11: Global metabolic disorders therapeutics market n growth lifecycle analysis
Exhibit 12: Top selling diabetes drugs based on sales 2015 ($ billions)
Exhibit 13: Market share of global diabetes drugs in global pharmaceutical market 2015
Exhibit 14: Global diabetes drugs market 2015-2020 ($ billions)
Exhibit 15: Global type 1 diabetes market 2015-2020 ($ billions)
Exhibit 16: Global type 2 diabetes drugs market 2015-2020 ($ billions)
Exhibit 17: Market share analysis of vendors in global diabetes drugs market
Exhibit 18: Revenues from the sales of top five products in global diabetes drugs market 2013-2015 ($ billions)
Exhibit 19: Revenues from the sales of top five products in hypercholesterolemia drugs market 2013-2015 ($ billions)
Exhibit 20: Market dynamics of hypercholesterolemia drugs
Exhibit 21: Percentage share of hypercholesterolemia drugs by drug class 2015
Exhibit 22: Global hypercholesterolemia drugs market 2015-2020 ($ billions)
Exhibit 23: Market share analysis of global hypercholesterolemia drugs market 2015
Exhibit 24: Products offered by major vendors in global hypercholesterolemia drugs market
Exhibit 25: Global lysosomal storage diseases drugs market 2015-2020 ($ billions)
Exhibit 26: Key events in treatment of lysosomal storage diseases
Exhibit 27: Products offered by major vendors in global lysosomal storage disorders drugs market
Exhibit 28: Global anti-obesity drugs market 2015-2020 ($ millions)
Exhibit 29: Products offered by major vendors in global anti-obesity drugs market
Exhibit 30: Global metabolic disorders therapeutics market by geography 2015-2020
Exhibit 31: Global metabolic disorder therapeutics market by geography 2015 and 2020
Exhibit 32: Global metabolic disorder therapeutics market by geography 2015-2020 ($ billions)
Exhibit 33: Global share of metabolic disorder therapeutics market by geography 2015
Exhibit 34: Global share of various metabolic disorder therapeutics market by geography based on disease type 2015
Exhibit 35: Global metabolic disorders therapeutics market by region: Market growth lifecycle analysis 2015
Exhibit 36: Metabolic disorder therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 37: Prevalence of obesity in various countries in Europe 2025
Exhibit 38: Metabolic disorders therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 39: Metabolic disorder therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 40: Prevalence of diabetes in selected countries in APAC 2007 and 2025
Exhibit 41: Few metabolic disorder drugs with patient assistance programs
Exhibit 42: Impact of drivers
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Oral insulin pipeline portfolio
Exhibit 45: Some investigational molecules for metabolic disorders and their mechanisms
Exhibit 46: Key vendors ranking 2015
Exhibit 47: Geographical presence of key vendors
Exhibit 48: Competitive scenario of global metabolic disorders therapeutics market vendors 2015-2020
Exhibit 49: Novo Nordisk: Profile
Exhibit 50: Novo Nordisk: Strength analysis
Exhibit 51: Novo Nordisk: Growth strategy matrix
Exhibit 52: Novo Nordisk: Growth opportunity assessment
Exhibit 53: Novo Nordisk: Business segmentation by revenue 2015
Exhibit 54: Novo Nordisk: Key products in diabetes and obesity care
Exhibit 55: Novo Nordisk: YoY growth and revenue generated from net product sales of human insulins 2012-2015 ($ billions)
Exhibit 56: Novo Nordisk: YoY growth and revenue generated from net product sales of Levemir 2012-2015 ($ billions)
Exhibit 57: Novo Nordisk: YoY growth and revenue of NovoRapid/ NovoLog 2012-2015 ($ billions)
Exhibit 58: Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog Mix 2012-2015 ($ billions)
Exhibit 59: Novo Nordisk: Revenue generated from net product sales of new-generation insulins 2013-2015 ($ millions)
Exhibit 60: Novo Nordisk: YoY growth and revenue of Victoza 2012-2015 ($ billions)
Exhibit 61: Novo Nordisk: YoY growth and revenue of Novonorm, Prandin, and Prandimet 2012-2014 ($ billions)
Exhibit 62: Sanofi: Business segmentation by revenue 2015
Exhibit 63: Sanofi: Profile
Exhibit 64: Sanofi: Strength analysis
Exhibit 65: Sanofi growth strategy matrix
Exhibit 66: Sanofi: Growth opportunity assessment
Exhibit 67: Key product offerings in diabetes market ($ billions)
Exhibit 68: Sanofi: YoY revenue and growth rate of Lantus 2012-2015 ($ billions)
Exhibit 69: Sanofi: YoY revenue and growth rate of Amaryl 2012-2015 ($ billions)
Exhibit 70: Sanofi: YoY revenue and growth rate of Apidra 2012-2015 ($ billions)
Exhibit 71: Sanofi: YoY revenue and growth rate of Insuman 2012-2015 ($ billions)
Exhibit 72: Sanofi: YoY revenue and growth rate of Lyxumia 2013-2015 ($ millions)
Exhibit 73: Sanofi: Revenues of lysosomal storage diseases drugs of Genzyme, 2015
Exhibit 74: Merck: Strength profile
Exhibit 75: Merck: Strength analysis
Exhibit 76: Merck: Growth strategy matrix
Exhibit 77: Merck: Opportunity assessment
Exhibit 78: Top selling diabetes drugs in 2015
Exhibit 79: Merck: Diabetes segmentation by revenue 2015
Exhibit 80: Merck: YoY growth and revenue of Janumet 2012-2015 ($ billions)
Exhibit 81: Merck: YoY growth and revenue of Januvia 2012-2015 ($ billions)
Exhibit 82: Merck: YoY revenue and growth rate of Zetia 2013-2015 ($ billions)
Exhibit 83: Merck: YoY revenue and growth rate of Vytorin 2013-2015 ($ billions)
Exhibit 84: Merck: YoY revenue and growth rate of Zocor 2013-2015 ($ millions)
Exhibit 85: AstraZeneca: Profile
Exhibit 86: AstraZeneca: Strength analysis
Exhibit 87: AstraZeneca: Growth strategy matrix
Exhibit 88: AstraZeneca: Opportunity assessment
Exhibit 89: Top selling diabetes drugs in 2015 ($ billions)
Exhibit 90: AstraZeneca: Byetta YoY growth and revenues 2012-2015 ($ billions)
Exhibit 91: Astrazeneca: Byetta YoY growth rate and revenues in the US ($ billions)
Exhibit 92: AstraZeneca: Bydureon YoY revenues and growth rate 2012-2015 ($ billions)
Exhibit 93: AstraZeneca: Onglyza YoY revenue and growth rate 2012-2015 ($ billions)
Exhibit 94: AstraZeneca: YoY revenue and growth rate of Crestor 2013-2015 ($ billions)
Exhibit 95: AstraZeneca: Geographical segmentation of Crestor 2015 by revenue
Exhibit 96: Eli Lilly: Profile
Exhibit 97: Eli Lilly: Strength analysis
Exhibit 98: Eli Lilly growth strategy matrix
Exhibit 99: Eli Lilly: Opportunity assessment
Exhibit 100: Top selling diabetic drugs 2015 ($ billions)
Exhibit 101: Eli Lilly: YoY revenue and growth rate of Humalog 2012-2015 ($ billions)
Exhibit 102: Eli Lilly: YoY revenue and growth rate of Humulin 2012-2015 ($ billions)
Exhibit 103: Eli Lilly: YoY revenue and growth rate of Tradjenta 2012-2015 ($ billions)
Exhibit 104: Eli Lilly: YoY revenue of Trylicity 2014-2015 ($ millions)
...
Publisher Name : Technavio

SIMILAR MARKET STUDIES

Please Select Format
Single User: US $ 2500
Five User: US $ 3000
Site User: US $ 4000
Global User: US $ 10000

NEED MORE INFORMATION
Contact us
Call us +1-971-202-1575
--- or ---
help@bigmarketresearch.com
WHY BIG MARKET RESEARCH
With high quality and penned to perfection, Big Market Research is an exclusive online market to get best market research reports for your business needs and strategies. We recommend you to stop browsing as soon as you discover our website. This is because we firmly believe that once you reach here; all your business concerns will be addressed.

We have a huge collection of market research report from numerous filed which will provide you with all the necessary solution. We make sure that reports that we sell are true in context, have a quality that is unrivaled, fully integrated with equal spread of opinion. They will give you proper insights into different opportunities one may locate for their start-up pr expansion.

Let your qualms and concern be sidelined through our high end syndicated as well as customized reports.
Top